HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Open to people ages 18 years and up

• Histologically confirmed UC originating from the renal pelvis, ureters, bladder, or urethra. Mixed-cell type tumors are eligible as long as urothelial cell carcinoma is the predominant cell type.
• Locally advanced unresectable or metastatic stage disease
• Formalin fixed paraffin embedded (FFPE) tumor tissue blocks (or freshly sectioned slides, see laboratory manual for details) available for HER2 testing.
• At least 1 prior line of systemic therapy for locally advanced unresectable or metastatic urothelial carcinoma (LA/mUC), including 1 line of platinum-containing chemotherapy.
• Initiation of anticancer therapy for UC after prior progression on platinum-based therapy with or without maintenance avelumab between 01 January 2019 and 12 months before the end of data collection
• Radiographically documented and measurable disease progression immediately before index date

• Any concurrent malignant neoplasm requiring systemic therapy during the study window
• Enrollment in a therapeutic clinical trial and received non-standard of care treatment during index line of therapy